Which has higher earnings and valuation, PRE or SEER?

Prenetics Global has higher revenue and earnings than Seer. Prenetics Global is trading at a lower price-to-earnings ratio than Seer, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Prenetics Global $92.39M 3.27 -$37.71M -$4.58 N/A Seer $16.58M 5.41 -$73.60M -$1.24 N/A

Is PRE or SEER more profitable?

Prenetics Global has a net margin of -62.45% compared to Seer's net margin of -464.78%. Prenetics Global's return on equity of -20.33% beat Seer's return on equity. Company Net Margins Return on Equity Return on Assets Prenetics Global -62.45% -20.33% -15.42% Seer -464.78% -26.58% -23.51%

Does the media prefer PRE or SEER?

In the previous week, Prenetics Global and Prenetics Global both had 5 articles in the media. Prenetics Global's average media sentiment score of 1.13 beat Seer's score of 0.82 indicating that Prenetics Global is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prenetics Global 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Seer 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, MASS or SEER?

908 Devices has higher revenue and earnings than Seer. 908 Devices is trading at a lower price-to-earnings ratio than Seer, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio 908 Devices $56.20M 5.97 $19.49M -$1.00 N/A Seer $16.58M 5.41 -$73.60M -$1.24 N/A

Is MASS or SEER more profitable?

908 Devices has a net margin of -62.40% compared to Seer's net margin of -464.78%. 908 Devices' return on equity of -14.03% beat Seer's return on equity. Company Net Margins Return on Equity Return on Assets 908 Devices -62.40% -14.03% -10.40% Seer -464.78% -26.58% -23.51%

Does the media favor MASS or SEER?

In the previous week, Seer had 1 more articles in the media than 908 Devices. MarketBeat recorded 5 mentions for Seer and 4 mentions for 908 Devices. Seer's average media sentiment score of 0.82 beat 908 Devices' score of 0.47 indicating that Seer is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 908 Devices 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Seer 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is SEER or LAB more profitable?

Standard BioTools has a net margin of 73.46% compared to Seer's net margin of -464.78%. Standard BioTools' return on equity of -8.18% beat Seer's return on equity. Company Net Margins Return on Equity Return on Assets Seer -464.78% -26.58% -23.51% Standard BioTools 73.46% -8.18% -6.43%

Does the media refer more to NAUT or SEER?

In the previous week, Seer had 3 more articles in the media than Nautilus Biotechnology. MarketBeat recorded 5 mentions for Seer and 2 mentions for Nautilus Biotechnology. Nautilus Biotechnology's average media sentiment score of 0.93 beat Seer's score of 0.82 indicating that Nautilus Biotechnology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nautilus Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Seer 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Seer (SEER) Competitors

$1.63 -0.03 (-1.81%)

Closing price 07/1/2026 04:00 PM Eastern

Extended Trading

$1.63 0.00 (0.00%)

As of 07/1/2026 04:04 PM Eastern

Compare

SEER vs. PRE, MASS, LAB, NAUT, and SENS

Should you buy Seer stock or one of its competitors? MarketBeat compares Seer with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Seer include Prenetics Global (PRE), 908 Devices (MASS), Standard BioTools (LAB), Nautilus Biotechnology (NAUT), and Senseonics Holdings, Inc. Common Stock (SENS). These companies are all part of the "measuring and control equipment" industry.

How does Seer compare to Prenetics Global?

Prenetics Global (NASDAQ:PRE) and Seer (NASDAQ:SEER) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, dividends, earnings, media sentiment and risk.

25.0% of Prenetics Global shares are held by institutional investors. Comparatively, 75.2% of Seer shares are held by institutional investors. 7.8% of Prenetics Global shares are held by company insiders. Comparatively, 11.3% of Seer shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Prenetics Global has higher revenue and earnings than Seer. Prenetics Global is trading at a lower price-to-earnings ratio than Seer, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prenetics Global	$92.39M	3.27	-$37.71M	-$4.58	N/A
Seer	$16.58M	5.41	-$73.60M	-$1.24	N/A

Prenetics Global has a net margin of -62.45% compared to Seer's net margin of -464.78%. Prenetics Global's return on equity of -20.33% beat Seer's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prenetics Global	-62.45%	-20.33%	-15.42%
Seer	-464.78%	-26.58%	-23.51%

Prenetics Global has a beta of 0.26, meaning that its stock price is 74% less volatile than the broader market. Comparatively, Seer has a beta of 1.59, meaning that its stock price is 59% more volatile than the broader market.

Prenetics Global presently has a consensus target price of $31.75, suggesting a potential upside of 77.47%. Seer has a consensus target price of $4.00, suggesting a potential upside of 145.40%. Given Seer's stronger consensus rating and higher possible upside, analysts plainly believe Seer is more favorable than Prenetics Global.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prenetics Global	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Seer	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, Prenetics Global and Prenetics Global both had 5 articles in the media. Prenetics Global's average media sentiment score of 1.13 beat Seer's score of 0.82 indicating that Prenetics Global is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prenetics Global	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Seer	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Seer beats Prenetics Global on 9 of the 16 factors compared between the two stocks.

How does Seer compare to 908 Devices?

908 Devices (NASDAQ:MASS) and Seer (NASDAQ:SEER) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, profitability, institutional ownership and media sentiment.

908 Devices has a net margin of -62.40% compared to Seer's net margin of -464.78%. 908 Devices' return on equity of -14.03% beat Seer's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
908 Devices	-62.40%	-14.03%	-10.40%
Seer	-464.78%	-26.58%	-23.51%

908 Devices has a beta of 0.63, meaning that its stock price is 37% less volatile than the broader market. Comparatively, Seer has a beta of 1.59, meaning that its stock price is 59% more volatile than the broader market.

88.1% of 908 Devices shares are owned by institutional investors. Comparatively, 75.2% of Seer shares are owned by institutional investors. 28.2% of 908 Devices shares are owned by insiders. Comparatively, 11.3% of Seer shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

908 Devices has higher revenue and earnings than Seer. 908 Devices is trading at a lower price-to-earnings ratio than Seer, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
908 Devices	$56.20M	5.97	$19.49M	-$1.00	N/A
Seer	$16.58M	5.41	-$73.60M	-$1.24	N/A

In the previous week, Seer had 1 more articles in the media than 908 Devices. MarketBeat recorded 5 mentions for Seer and 4 mentions for 908 Devices. Seer's average media sentiment score of 0.82 beat 908 Devices' score of 0.47 indicating that Seer is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
908 Devices	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Seer	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

908 Devices currently has a consensus target price of $12.00, indicating a potential upside of 35.14%. Seer has a consensus target price of $4.00, indicating a potential upside of 145.40%. Given Seer's stronger consensus rating and higher probable upside, analysts plainly believe Seer is more favorable than 908 Devices.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
908 Devices	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Seer	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

908 Devices beats Seer on 10 of the 17 factors compared between the two stocks.

How does Seer compare to Standard BioTools?

Seer (NASDAQ:SEER) and Standard BioTools (NASDAQ:LAB) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, dividends, earnings, media sentiment, risk and profitability.

Standard BioTools has a net margin of 73.46% compared to Seer's net margin of -464.78%. Standard BioTools' return on equity of -8.18% beat Seer's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Seer	-464.78%	-26.58%	-23.51%
Standard BioTools	73.46%	-8.18%	-6.43%

75.2% of Seer shares are held by institutional investors. Comparatively, 53.7% of Standard BioTools shares are held by institutional investors. 11.3% of Seer shares are held by company insiders. Comparatively, 26.8% of Standard BioTools shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Seer presently has a consensus target price of $4.00, suggesting a potential upside of 145.40%. Standard BioTools has a consensus target price of $1.35, suggesting a potential upside of 56.25%. Given Seer's stronger consensus rating and higher probable upside, analysts plainly believe Seer is more favorable than Standard BioTools.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Seer	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	2 Strong Buy rating(s)	3.00
Standard BioTools	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

In the previous week, Seer had 4 more articles in the media than Standard BioTools. MarketBeat recorded 5 mentions for Seer and 1 mentions for Standard BioTools. Standard BioTools' average media sentiment score of 1.87 beat Seer's score of 0.82 indicating that Standard BioTools is being referred to more favorably in the news media.

Company	Overall Sentiment
Seer	Positive
Standard BioTools	Very Positive

Seer has higher earnings, but lower revenue than Standard BioTools. Seer is trading at a lower price-to-earnings ratio than Standard BioTools, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Seer	$16.58M	5.41	-$73.60M	-$1.24	N/A
Standard BioTools	$85.33M	3.95	-$74.90M	$0.20	4.32

Seer has a beta of 1.59, indicating that its share price is 59% more volatile than the broader market. Comparatively, Standard BioTools has a beta of 1.43, indicating that its share price is 43% more volatile than the broader market.

Summary

Seer and Standard BioTools tied by winning 8 of the 16 factors compared between the two stocks.

How does Seer compare to Nautilus Biotechnology?

Nautilus Biotechnology (NASDAQ:NAUT) and Seer (NASDAQ:SEER) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, analyst recommendations, dividends, profitability, valuation, risk and earnings.

Nautilus Biotechnology has higher earnings, but lower revenue than Seer. Nautilus Biotechnology is trading at a lower price-to-earnings ratio than Seer, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nautilus Biotechnology	N/A	N/A	-$59M	-$0.46	N/A
Seer	$16.58M	5.41	-$73.60M	-$1.24	N/A

In the previous week, Seer had 3 more articles in the media than Nautilus Biotechnology. MarketBeat recorded 5 mentions for Seer and 2 mentions for Nautilus Biotechnology. Nautilus Biotechnology's average media sentiment score of 0.93 beat Seer's score of 0.82 indicating that Nautilus Biotechnology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nautilus Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Seer	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Nautilus Biotechnology has a beta of 0.81, meaning that its share price is 19% less volatile than the broader market. Comparatively, Seer has a beta of 1.59, meaning that its share price is 59% more volatile than the broader market.

Nautilus Biotechnology currently has a consensus price target of $4.00, suggesting a potential upside of 117.39%. Seer has a consensus price target of $4.00, suggesting a potential upside of 145.40%. Given Seer's stronger consensus rating and higher possible upside, analysts clearly believe Seer is more favorable than Nautilus Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nautilus Biotechnology	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Seer	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	2 Strong Buy rating(s)	3.00

50.7% of Nautilus Biotechnology shares are held by institutional investors. Comparatively, 75.2% of Seer shares are held by institutional investors. 41.1% of Nautilus Biotechnology shares are held by company insiders. Comparatively, 11.3% of Seer shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Nautilus Biotechnology has a net margin of 0.00% compared to Seer's net margin of -464.78%. Seer's return on equity of -26.58% beat Nautilus Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nautilus Biotechnology	N/A	-35.04%	-29.16%
Seer	-464.78%	-26.58%	-23.51%

Summary

Seer beats Nautilus Biotechnology on 10 of the 16 factors compared between the two stocks.

How does Seer compare to Senseonics Holdings, Inc. Common Stock?

Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS) and Seer (NASDAQ:SEER) are both small-cap measuring and control equipment companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, valuation, institutional ownership, analyst recommendations and media sentiment.

Senseonics Holdings, Inc. Common Stock has higher revenue and earnings than Seer. Senseonics Holdings, Inc. Common Stock is trading at a lower price-to-earnings ratio than Seer, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Senseonics Holdings, Inc. Common Stock	$35.26M	6.35	-$69.11M	-$2.00	N/A
Seer	$16.58M	5.41	-$73.60M	-$1.24	N/A

Senseonics Holdings, Inc. Common Stock currently has a consensus price target of $17.00, indicating a potential upside of 217.16%. Seer has a consensus price target of $4.00, indicating a potential upside of 145.40%. Given Senseonics Holdings, Inc. Common Stock's higher probable upside, analysts clearly believe Senseonics Holdings, Inc. Common Stock is more favorable than Seer.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Senseonics Holdings, Inc. Common Stock	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Seer	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	2 Strong Buy rating(s)	3.00

Senseonics Holdings, Inc. Common Stock has a net margin of -213.87% compared to Seer's net margin of -464.78%. Seer's return on equity of -26.58% beat Senseonics Holdings, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Senseonics Holdings, Inc. Common Stock	-213.87%	-129.97%	-67.14%
Seer	-464.78%	-26.58%	-23.51%

In the previous week, Seer had 4 more articles in the media than Senseonics Holdings, Inc. Common Stock. MarketBeat recorded 5 mentions for Seer and 1 mentions for Senseonics Holdings, Inc. Common Stock. Senseonics Holdings, Inc. Common Stock's average media sentiment score of 1.44 beat Seer's score of 0.82 indicating that Senseonics Holdings, Inc. Common Stock is being referred to more favorably in the media.

Company	Overall Sentiment
Senseonics Holdings, Inc. Common Stock	Positive
Seer	Positive

Senseonics Holdings, Inc. Common Stock has a beta of 0.99, indicating that its stock price is 1% less volatile than the broader market. Comparatively, Seer has a beta of 1.59, indicating that its stock price is 59% more volatile than the broader market.

12.4% of Senseonics Holdings, Inc. Common Stock shares are owned by institutional investors. Comparatively, 75.2% of Seer shares are owned by institutional investors. 4.7% of Senseonics Holdings, Inc. Common Stock shares are owned by insiders. Comparatively, 11.3% of Seer shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Seer beats Senseonics Holdings, Inc. Common Stock on 10 of the 17 factors compared between the two stocks.

Get Seer News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SEER and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SEER vs. The Competition

Export

Metric	Seer	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$91.27M	$3.67B	$6.79B	$12.59B
Dividend Yield	N/A	2.21%	2.66%	6.14%
P/E Ratio	-1.31	21.28	27.41	25.27
Price / Sales	5.41	324.28	530.69	99.42
Price / Cash	N/A	141.54	47.99	59.26
Price / Book	0.35	8.71	11.04	6.62
Net Income	-$73.60M	$23.87M	$3.57B	$336.83M
7 Day Performance	-5.78%	4.34%	2.92%	3.25%
1 Month Performance	-12.83%	6.62%	3.74%	0.92%
1 Year Performance	-26.24%	61.64%	34.44%	27.62%

Seer Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SEER Seer	4.3651 of 5 stars	$1.63 -1.8%	$4.00 +145.4%	-25.6%	$91.27M	$16.58M	N/A	160	Short Interest Decrease Gap Up High Trading Volume
PRE Prenetics Global	3.6892 of 5 stars	$19.92 -0.2%	$31.75 +59.4%	+116.1%	$336.81M	$92.39M	N/A	1	Positive News
MASS 908 Devices	2.0319 of 5 stars	$8.73 +0.8%	$12.00 +37.5%	+37.0%	$327.47M	$57.80M	N/A	60
LAB Standard BioTools	4.0033 of 5 stars	$0.79 +2.3%	$1.35 +70.4%	-33.0%	$302.14M	$85.33M	3.96	620	Positive News
NAUT Nautilus Biotechnology	3.0742 of 5 stars	$2.33 +0.9%	$4.00 +71.7%	+152.1%	$293.55M	N/A	N/A	130

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SEER) was last updated on 7/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Seer (SEER) Competitors

SEER vs. PRE, MASS, LAB, NAUT, and SENS

How does Seer compare to Prenetics Global?

Summary

How does Seer compare to 908 Devices?

Summary

How does Seer compare to Standard BioTools?

Summary

How does Seer compare to Nautilus Biotechnology?

Summary

How does Seer compare to Senseonics Holdings, Inc. Common Stock?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SEER vs. The Competition

Seer Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Seer (SEER) Competitors

SEER vs. PRE, MASS, LAB, NAUT, and SENS

How does Seer compare to Prenetics Global?

Do institutionals & insiders hold more shares of PRE or SEER?

Which has higher earnings and valuation, PRE or SEER?

Is PRE or SEER more profitable?

Which has more volatility & risk, PRE or SEER?

Do analysts rate PRE or SEER?

Does the media prefer PRE or SEER?

Summary

How does Seer compare to 908 Devices?

Is MASS or SEER more profitable?

Which has more risk & volatility, MASS or SEER?

Do institutionals and insiders hold more shares of MASS or SEER?

Which has preferable valuation & earnings, MASS or SEER?

Does the media favor MASS or SEER?

Do analysts prefer MASS or SEER?

Summary

How does Seer compare to Standard BioTools?

Is SEER or LAB more profitable?

Do institutionals and insiders believe in SEER or LAB?

Do analysts rate SEER or LAB?

Does the media favor SEER or LAB?

Which has better earnings & valuation, SEER or LAB?

Which has more risk & volatility, SEER or LAB?

Summary

How does Seer compare to Nautilus Biotechnology?

Which has preferable earnings & valuation, NAUT or SEER?

Does the media refer more to NAUT or SEER?

Which has more volatility and risk, NAUT or SEER?

Do analysts prefer NAUT or SEER?

Do institutionals & insiders believe in NAUT or SEER?

Is NAUT or SEER more profitable?

Summary

How does Seer compare to Senseonics Holdings, Inc. Common Stock?

Which has preferable valuation & earnings, SENS or SEER?

Do analysts recommend SENS or SEER?

Is SENS or SEER more profitable?

Does the media refer more to SENS or SEER?

Which has more volatility and risk, SENS or SEER?

Do insiders and institutionals have more ownership in SENS or SEER?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SEER vs. The Competition

Seer Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools